Mexiletine Hydrochloride Market Report 2026

Mexiletine Hydrochloride Market Overview

• Mexiletine Hydrochloride market size has reached to $1.29 billion in 2025 • Expected to grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.4% • Growth Driver: Increasing Number Of Cardiovascular Diseases Fueling The Market Growth Due To Rising Healthcare Burden • Market Trend: Innovative Generic Capsules Enhance Accessibility, Affordability, And Patient Compliance • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mexiletine Hydrochloride Market?

Mexiletine hydrochloride is a prescription drug used to treat serious irregular heart rhythms, especially ventricular arrhythmias in the lower chambers of the heart. As a sodium channel blocker, it stabilizes the heart’s electrical activity and helps maintain a regular heartbeat. It may also be prescribed for certain nerve and muscle disorders, where it helps reduce symptoms caused by overactive nerves or muscle dysfunction. The main product types of mexiletine hydrochloride are capsules, tablets, injections, and other product types. Capsules are solid dosage forms with a dissolvable shell that encases precise amounts of medication, allowing for easy swallowing and controlled release. It is distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. It is used for applications such as arrhythmias, neuropathic pain, myotonic disorders, and other indications, and is utilized by end-users including hospitals, clinics, homecare settings, and other healthcare providers.

What Is The Mexiletine Hydrochloride Market Growth Forecast?

The mexiletine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increasing aging population with cardiac disorders, rising demand for cost-effective cardiac drugs, expansion of home-based cardiac care, growing focus on neuropathic pain management, increasing availability of generic formulations. Major trends in the forecast period include increasing use of sodium channel blockers in cardiac care, rising adoption of oral antiarrhythmic therapies, growing focus on neuromuscular disorder treatments, expansion of generic drug manufacturing, enhanced emphasis on long-term cardiac rhythm management.

Global Mexiletine Hydrochloride Market Segmentation

1) By Product Type: Capsules, Tablets, Injection, Other Product Types 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 3) By Application: Arrhythmias, Neuropathic Pain, Myotonic Disorders, Other Applications 4) By End-User: Hospitals, Clinics, Homecare, Other End-Users Subsegments: 1) By Capsules: Extended Release Capsules, Immediate Release Capsules 2) By Tablets: Film Coated Tablets, Chewable Tablets, Dispersible Tablets 3) By Injection: Intravenous Injection, Intramuscular Injection, Subcutaneous Injection 4) By Other Product Types: Oral Suspension, Topical Solution, Compounded Formulations

What Is The Driver Of The Mexiletine Hydrochloride Market?

The increasing number of cardiovascular diseases is expected to propel the growth of the mexiletine hydrochloride market going forward. Cardiovascular diseases are disorders of the heart and blood vessels that include coronary heart disease, cerebrovascular disease, and other heart-related conditions. The rising incidence of cardiovascular diseases is due to aging populations and sedentary lifestyles, as longer life expectancy combined with reduced physical activity and poor dietary habits significantly increase the risk of developing heart-related conditions. Mexiletine hydrochloride works by blocking certain electrical signals and sodium channels in the heart to stabilize irregular heart rhythms, making it an effective treatment for ventricular arrhythmias and other cardiac rhythm disorders associated with cardiovascular diseases. For instance, in August 2025, according to the National Institutes of Health (NIH), a Bethesda-based largest biomedical research agency in the world, projections indicate that from 2025 to 2050, cardiovascular prevalence will rise by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, with annual cardiovascular deaths expected to climb from 20.5 million to 35.6 million. Therefore, the increasing number of cardiovascular diseases is driving the growth of the mexiletine hydrochloride industry.

Key Players In The Global Mexiletine Hydrochloride Market

Major companies operating in the mexiletine hydrochloride market are Teva Pharmaceuticals Industries Ltd., Macleods Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Alembic Pharmaceuticals Limited, ANI Pharmaceuticals Inc., Taj Pharmaceuticals Limited, Biophore India Pharmaceuticals Pvt. Ltd., Professional Compounding Centers of America Inc. (PCCA), Medichem S.A., Camber Pharmaceuticals Inc., Ingenus Pharmaceuticals LLC, AGC Pharma Chemicals Europe S.L.U., Rivopharm S.A., Kalintis Healthcare Pvt. Ltd., Senores Pharmaceuticals Inc., Midas Pharma GmbH, Tooba Pharmaceuticals Private Limited, Changzhou Yabang Pharmaceutical Co. Ltd., Shreeji Pharma International

Global Mexiletine Hydrochloride Market Trends and Insights

Major companies operating in the Mexiletine Hydrochloride market are focusing on developing innovative solutions, such as generic capsule formulations to improve accessibility, affordability, and patient compliance. Generic capsule formulations are versions of branded drugs that contain the same active ingredient, strength, and dosage form, but are typically more affordable and widely accessible. For instance, in June 2023, Camber Pharmaceuticals Inc., a US-based generic pharmaceutical company, launched Mexiletine Hydrochloride Capsules, USP, available in 150 mg, 200 mg, and 250 mg strengths. This launch offers three unique advantages: it provides dose-specific flexibility through multiple strengths, features high-count 100-bottle packaging that supports long-term use, and delivers a cost-effective generic alternative to branded Mexitil, thereby enhancing accessibility for patients.

What Are Latest Mergers And Acquisitions In The Mexiletine Hydrochloride Market?

In January 2025, Lupin Limited, an India-based pharmaceutical company specializing in mexiletine hydrochloride, partnered with Avas Pharmaceuticals SRL to launch NaMuscla in Italy for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. With this partnership, Lupin Limited and Avas Pharmaceuticals SRL aim to introduce and ensure consistent access to the first licensed treatment for myotonia in Italy, addressing unmet medical needs, supporting patients throughout their treatment journey, and improving overall quality of life through a safe and effective therapeutic option. Avas Pharmaceuticals SRL is an Italy-based company focused on commercializing innovative therapies for rare and specialized diseases.

Regional Insights

North America was the largest region in the mexiletine hydrochloride market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Mexiletine Hydrochloride Market?

The mexiletine hydrochloride market consists of sales of mexitil and namuscla. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Mexiletine Hydrochloride Market Report 2026?

The mexiletine hydrochloride market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mexiletine hydrochloride industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.